Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli

Hui Chen; Jun-Sheng Chen; Pameila Paerhati; Tanja Jakos; Si-Yi Bai; Jian-Wei Zhu; Yun-Sheng Yuan

doi:10.1055/s-0041-1735145

Pharmaceutical Fronts, Inhaltsverzeichnis

CC BY 4.0 · Pharmaceutical Fronts 2021; 03(02): e39-e49
DOI: 10.1055/s-0041-1735145

Review Article

Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli

Authors

Hui Chen‡^#

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
Jun-Sheng Chen‡^#

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
Pameila Paerhati

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
Tanja Jakos

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
Si-Yi Bai

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
Jian-Wei Zhu

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
Yun-Sheng Yuan

¹Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China

Abstract

With the advancement of genetic engineering, monoclonal antibodies (mAbs) have made far-reaching progress in the treatment of various human diseases. However, due to the high cost of production, the increasing demands for antibody-based therapies have not been fully met. Currently, mAb-derived alternatives, such as antigen-binding fragments (Fab), single-chain variable fragments, bispecifics, nanobodies, and conjugated mAbs have emerged as promising new therapeutic modalities. They can be readily prepared in bacterial systems with well-established fermentation technology and ease of manipulation, leading to the reduction of overall cost. This review aims to shed light on the strategies to improve the expression, purification, and yield of Fab fragments in Escherichia coli expression systems, as well as current advances in the applications of Fab fragments.

Keywords

mAbs - Fab - E. coli expression systems - applications

Volltext

Referenzen

References
1 Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs 2019; 11 (02) 219-238
2 Alibakhshi A, Abarghooi Kahaki F, Ahangarzadeh S. et al. Targeted cancer therapy through antibody fragments-decorated nanomedicines. J Control Release 2017; 268: 323-334
3 Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol 2018; 36 (12) 1136-1145
4 Ma H, O'Kennedy R. Recombinant antibody fragment production. Methods 2017; 116: 23-33
5 Rader C. Overview on concepts and applications of Fab antibody fragments. Curr Protoc Protein Sci 2009; Chapter 6: Unit 6.9
6 Bever CS, Dong JX, Vasylieva N. et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem 2016; 408 (22) 5985-6002
7 de Aguiar RB, da Silva TA, Costa BA. et al. Generation and functional characterization of a single-chain variable fragment (scFv) of the anti-FGF2 3F12E7 monoclonal antibody. Sci Rep 2021; 11 (01) 1432
8 Koerber JT, Hornsby MJ, Wells JA. An improved single-chain Fab platform for efficient display and recombinant expression. J Mol Biol 2015; 427 (02) 576-586
9 Kirley TL, Greis KD, Norman AB. Selective disulfide reduction for labeling and enhancement of Fab antibody fragments. Biochem Biophys Res Commun 2016; 480 (04) 752-757
10 An Y, Zhang Y, Mueller HM, Shameem M, Chen X. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization. MAbs 2014; 6 (04) 879-893
11 Venturi M, Seifert C, Hunte C. High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J Mol Biol 2002; 315 (01) 1-8
12 Spadiut O, Capone S, Krainer F, Glieder A, Herwig C. Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 2014; 32 (01) 54-60
13 Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: a case study prior to pharmaceutical development. N Biotechnol 2018; 44: 31-40
14 Backovic M, Johansson DX, Klupp BG, Mettenleiter TC, Persson MA, Rey FA. Efficient method for production of high yields of Fab fragments in Drosophila S2 cells. Protein Eng Des Sel 2010; 23 (04) 169-174
15 Vazquez-Lombardi R, Nevoltris D, Luthra A, Schofield P, Zimmermann C, Christ D. Transient expression of human antibodies in mammalian cells. Nat Protoc 2018; 13 (01) 99-117
16 Gaciarz A, Veijola J, Uchida Y. et al. Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Microb Cell Fact 2016; 15 (01) 22
17 Kwong KY, Rader C. E. coli expression and purification of fab antibody fragments. Curr Protoc Protein Sci. 2009. Chapter 6. Unit 6.10
18 Stewart EJ, Aslund F, Beckwith J. Disulfide bond formation in the Escherichia coli cytoplasm: an in vivo role reversal for the thioredoxins. EMBO J 1998; 17 (19) 5543-5550
19 Derman AI, Prinz WA, Belin D, Beckwith J. Mutations that allow disulfide bond formation in the cytoplasm of Escherichia coli. Science 1993; 262 (5140): 1744-1747
20 Graumann K, Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006; 1 (02) 164-186
21 Burgess RR. Refolding solubilized inclusion body proteins. Methods Enzymol 2009; 463: 259-282
22 González-Montalban N, García-Fruitós E, Ventura S. et al. Comparative analysis of E. coli inclusion bodies and thermal protein aggregates. Microb Cell Fact 2006; 5 (01) 16
23 Friedrich L, Stangl S, Hahne H. et al. Bacterial production and functional characterization of the Fab fragment of the murine IgG1/lambda monoclonal antibody cmHsp70.1, a reagent for tumour diagnostics. Protein Eng Des Sel 2010; 23 (04) 161-168
24 Rezaie F, Davami F, Mansouri K. et al. Cytosolic expression of functional Fab fragments in Escherichia coli using a novel combination of dual SUMO expression cassette and EnBase^® cultivation mode. J Appl Microbiol 2017; 123 (01) 134-144
25 Ojima-Kato T, Fukui K, Yamamoto H. et al. ‘Zipbody’ leucine zipper-fused Fab in E. coli in vitro and in vivo expression systems. Protein Eng Des Sel 2016; 29 (04) 149-157
26 Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng 2005; 99 (04) 303-310
27 Vallejo LF, Rinas U. Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins. Microb Cell Fact 2004; 3 (01) 11
28 Rinas U, Hoffmann F, Betiku E, Estapé D, Marten S. Inclusion body anatomy and functioning of chaperone-mediated in vivo inclusion body disassembly during high-level recombinant protein production in Escherichia coli. J Biotechnol 2007; 127 (02) 244-257
29 Singh A, Upadhyay V, Upadhyay AK, Singh SM, Panda AK. Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb Cell Fact 2015; 14 (01) 41
30 Misawa S, Kumagai I. Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies. Biopolymers 1999; 51 (04) 297-307
31 Arora D, Khanna N. Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J Biotechnol 1996; 52 (02) 127-133
32 Buchner J, Rudolph R. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N Y) 1991; 9 (02) 157-162
33 Luo M, Zhao M, Cagliero C. et al. A general platform for efficient extracellular expression and purification of Fab from Escherichia coli. Appl Microbiol Biotechnol 2019; 103 (08) 3341-3353
34 Ellis M, Patel P, Edon M, Ramage W, Dickinson R, Humphreys DP. Development of a high yielding E. coli periplasmic expression system for the production of humanized Fab' fragments. Biotechnol Prog 2017; 33 (01) 212-220
35 Gupta SK, Shukla P. Microbial platform technology for recombinant antibody fragment production: a review. Crit Rev Microbiol 2017; 43 (01) 31-42
36 Corisdeo S, Wang B. Functional expression and display of an antibody Fab fragment in Escherichia coli: study of vector designs and culture conditions. Protein Expr Purif 2004; 34 (02) 270-279
37 Lin B, Renshaw MW, Autote K. et al. A step-wise approach significantly enhances protein yield of a rationally-designed agonist antibody fragment in E. coli. Protein Expr Purif 2008; 59 (01) 55-63
38 Gupta SK, Shukla P. Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications. Crit Rev Biotechnol 2016; 36 (06) 1089-1098
39 Thie H, Schirrmann T, Paschke M, Dübel S, Hust M. SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. N Biotechnol 2008; 25 (01) 49-54
40 Nagano R, Masuda K. Establishment of a signal peptide with cross-species compatibility for functional antibody expression in both Escherichia coli and Chinese hamster ovary cells. Biochem Biophys Res Commun 2014; 447 (04) 655-659
41 Burioni R, Plaisant P, Bugli F, Delli Carri V, Clementi M, Fadda G. A vector for the expression of recombinant monoclonal Fab fragments in bacteria. J Immunol Methods 1998; 217 (1–2): 195-199
42 Levy R, Weiss R, Chen G, Iverson BL, Georgiou G. Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif 2001; 23 (02) 338-347
43 Kumar S, Kalsi J, Ravirajan CT. et al. Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab. J Biol Chem 2000; 275 (45) 35129-35136
44 Elena C, Ravasi P, Castelli ME, Peirú S, Menzella HG. Expression of codon optimized genes in microbial systems: current industrial applications and perspectives. Front Microbiol 2014; 5: 21
45 Nissley DA, Sharma AK, Ahmed N. et al. Accurate prediction of cellular co-translational folding indicates proteins can switch from post- to co-translational folding. Nat Commun 2016; 7: 10341
46 Goodman DB, Church GM, Kosuri S. Causes and effects of N-terminal codon bias in bacterial genes. Science 2013; 342 (6157): 475-479
47 Zalucki YM, Jennings MP. Experimental confirmation of a key role for non-optimal codons in protein export. Biochem Biophys Res Commun 2007; 355 (01) 143-148
48 Pechmann S, Chartron JW, Frydman J. Local slowdown of translation by nonoptimal codons promotes nascent-chain recognition by SRP in vivo. Nat Struct Mol Biol 2014; 21 (12) 1100-1105
49 Kulmala A, Huovinen T, Lamminmäki U. Improvement of Fab expression by screening combinatorial synonymous signal sequence libraries. Microb Cell Fact 2019; 18 (01) 157
50 Khow O, Suntrarachun S. Strategies for production of active eukaryotic proteins in bacterial expression system. Asian Pac J Trop Biomed 2012; 2 (02) 159-162
51 Chung KT, Lee TH, Kang GS. Isolation of proteins that speifically interact with the ATPase domain of mammalian ER chaperone, BiP. Biotechnol Bioprocess Eng 2003; 8 (03) 192-198
52 Ow DS, Lim DY, Nissom PM, Camattari A, Wong VV. Co-expression of Skp and FkpA chaperones improves cell viability and alters the global expression of stress response genes during scFvD1.3 production. Microb Cell Fact 2010; 9: 22
53 Webb HM, Ruddock LW, Marchant RJ, Jonas K, Klappa P. Interaction of the periplasmic peptidylprolyl cis-trans isomerase SurA with model peptides. The N-terminal region of SurA id essential and sufficient for peptide binding. J Biol Chem 2001; 276 (49) 45622-45627
54 Rodriguez-Carmona E, Cano-Garrido O, Dragosits M. et al. Recombinant Fab expression and secretion in Escherichia coli continuous culture at medium cell densities: Influence of temperature. Process Biochem 2012; 47 (03) 446-452
55 Yang Q, Xu J, Li M, Lei X, An L. High-level expression of a soluble snake venom enzyme, gloshedobin, in E. coli in the presence of metal ions. Biotechnol Lett 2003; 25 (08) 607-610
56 Kim SJ, Ha GS, Lee G. et al. Enhanced expression of soluble antibody fragments by low-temperature and overdosing with a nitrogen source. Enzyme Microb Technol 2018; 115: 9-15
57 An F, Chen YC, Fan LY, Han HX. Fed-batch fermentation of Escherichia coli that express fab fragment of anti-HBsAg [in Chinese]. Sheng Wu Gong Cheng Xue Bao 2003; 19 (01) 87-91
58 O'Brien PM, Maxwell G, Campo MS. Bacterial expression and purification of recombinant bovine Fab fragments. Protein Expr Purif 2002; 24 (01) 43-50
59 Bäcklund E, Reeks D, Markland K, Weir N, Bowering L, Larsson G. Fedbatch design for periplasmic product retention in Escherichia coli. J Biotechnol 2008; 135 (04) 358-365
60 Ukkonen K, Veijola J, Vasala A, Neubauer P. Effect of culture medium, host strain and oxygen transfer on recombinant Fab antibody fragment yield and leakage to medium in shaken E. coli cultures. Microb Cell Fact 2013; 12: 73
61 Schofield DM, Templar A, Newton J, Nesbeth DN. Promoter engineering to optimize recombinant periplasmic Fab' fragment production in Escherichia coli. Biotechnol Prog 2016; 32 (04) 840-847
62 Chodorge M, Züger S, Stirnimann C. et al. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ 2012; 19 (07) 1187-1195
63 Holzer W, Petersen F, Strittmatter W, Matzku S, von Hoegen I. A fusion protein of IL-8 and a Fab antibody fragments binds to IL-8 receptors and induces neutrophil activation. Cytokine 1996; 8 (03) 214-221
64 Nelke J, Medler J, Weisenberger D, Beilhack A, Wajant H. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism. MAbs 2020; 12 (01) 1807721
65 Bauss F, Lechmann M, Krippendorff B-F. et al. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Mol Oncol 2016; 10 (08) 1317-1329
66 Nascimento A, Mullerpatan A, Azevedo AM, Karande P, Cramer S. Development of phage biopanning strategies to identify affinity peptide ligands for kappa light chain Fab fragments. Biotechnol Prog 2019; 35 (06) e2884
67 Zhao Y, Gutshall L, Jiang H. et al. Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: Papain digestion of mAb and transient expression in mammalian cells. Protein Expr Purif 2009; 67 (02) 182-189
68 Malpiedi LP, Díaz CA, Nerli BB. et al. Single-chain antibody fragments: purification methodologies. Process Biochem 2013; 48 (08) 1242-1251
69 McMahon MJ, O'Kennedy R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods 2000; 241 (1–2): 1-10
70 Alves NJ, Stimple SD, Handlogten MW, Ashley JD, Kiziltepe T, Bilgicer B. Small-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targeting. Anal Chem 2012; 84 (18) 7721-7728
71 Spooner J, Keen J, Nayyar K. et al. Evaluation of strategies to control Fab light chain dimer during mammalian expression and purification: a universal one-step process for purification of correctly assembled Fab. Biotechnol Bioeng 2015; 112 (07) 1472-1477
72 Jalalirad R. Efficient chromatographic processes for elevated purification of antibody fragment (Fab D1.3) from crude escherichia coli culture. Biotechnology 2013; 12 (02) 74-80
73 Rouby G, Tran NT, Leblanc Y, Taverna M, Bihoreau N. Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry. MAbs 2020; 12 (01) e1781743
74 Nasiri H, Valedkarimi Z, Aghebati-Maleki L. et al. Production and purification of polyclonal antibody against F(ab')2 fragment of human immunoglobulin G. Vet Res Forum 2017; 8 (04) 307-312
75 Smith AG, Kaiser PK. Therapeutic monoclonal antibodies and fragments: Ranibizumab. Dev Ophthalmol 2016; 55: 246-251
76 Nakamura H, Oda-Ueda N, Ueda T, Ohkuri T. A novel engineered interchain disulfide bond in the constant region enhances the thermostability of adalimumab Fab. Biochem Biophys Res Commun 2018; 495 (01) 7-11
77 Campanati A, Benfaremo D, Luchetti MM, Ganzetti G, Gabrielli A, Offidani A. Certolizumab pegol for the treatment of psoriasis. Expert Opin Biol Ther 2017; 17 (03) 387-394
78 Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2017; 9 (09) CD007649
79 Goel N, Stephens S. Certolizumab pegol. MAbs 2010; 2 (02) 137-147
80 Kanje S, von Witting E, Chiang SC, Bryceson YT, Hober S. Site-specific photolabeling of the IgG Fab fragment using a small protein G derived domain. Bioconjug Chem 2016; 27 (09) 2095-2102
81 Zhou Z, Zhang J, Zhang Y, Ma G, Su Z. Specific conjugation of the hinge region for homogeneous preparation of antibody fragment-drug conjugate: a case study for doxorubicin-PEG-anti-CD20 Fab' synthesis. Bioconjug Chem 2016; 27 (01) 238-246
82 Kornberger P, Skerra A. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin. MAbs 2014; 6 (02) 354-366
83 Huang R, Sheng Y, Wei D, Yu J, Chen H, Jiang B. Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. Eur J Med Chem 2020; 190: 112080
84 Wissler HL, Ehlerding EB, Lyu Z. et al. Site-specific immuno-PET tracer to image PD-L1. Mol Pharm 2019; 16 (05) 2028-2036
85 Khalili H, Godwin A, Choi JW, Lever R, Khaw PT, Brocchini S. Fab-PEG-Fab as a potential antibody mimetic. Bioconjug Chem 2013; 24 (11) 1870-1882
86 Mori A, Ojima-Kato T, Kojima T, Nakano H. Zipbodyzyme: development of new antibody-enzyme fusion proteins. J Biosci Bioeng 2018; 125 (06) 637-643
87 Ritthisan P, Ojima-Kato T, Damnjanović J, Kojima T, Nakano H. SKIK-zipbody-alkaline phosphatase, a novel antibody fusion protein expressed in Escherichia coli cytoplasm. J Biosci Bioeng 2018; 126 (06) 705-709
88 Kang HJ, Kim HJ, Jung MS, Han JK, Cha SH. Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule. Immunol Lett 2017; 184: 34-42
89 Du J, Cao Y, Liu Y. et al. Engineering bifunctional antibodies with constant region fusion architectures. J Am Chem Soc 2017; 139 (51) 18607-18615
90 Rodriguez C, Nam DH, Kruchowy E, Ge X. Efficient antibody assembly in E. coli periplasm by disulfide bond folding factor co-expression and culture optimization. Appl Biochem Biotechnol 2017; 183 (02) 520-529
91 Fink M, Vazulka S, Egger E. et al. Microbioreactor cultivations of Fab-producing Escherichia coli reveal genome-integrated systems as suitable for prospective studies on direct Fab expression effects. Biotechnol J 2019; 14 (11) e1800637
92 Dariushnejad H, Farajnia S, Zarghami N. et al. Effect of DnaK/DnaJ/GrpE and DsbC chaperons on periplasmic expression of Fab antibody by E. coli SEC pathway. Int J Pept Res 2019; 25 (01) 67-74
93 Rodríguez-Martínez LM, Marquez-Ipiña AR, López-Pacheco F. et al. Antibody derived peptides for detection of Ebola virus glycoprotein. PLoS One 2015; 10 (10) e0135859